Asterias' oligodendrocyte progenitor cell therapy improves motor function in SCI patients at 12 months

Asterias Biotherapeutics Inc. (NYSE-A:AST) reported 12-month data from the Phase I/IIa SCiStar trial to treat cervical spinal cord injury (SCI) showing that 21 of 22 patients

Read the full 264 word article

User Sign In